0.650
0.00 (0.00%)
| Previous Close | 0.650 |
| Open | 0.670 |
| Volume | 506,400 |
| Avg. Volume (3M) | 379,981 |
| Market Cap | 60,327,488 |
| Price / Earnings (Forward) | 14.99 |
| Price / Sales | 0.480 |
| Price / Book | 0.500 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -17.27% |
| Operating Margin (TTM) | -27.35% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | -2.40% |
| Total Debt/Equity (MRQ) | 33.26% |
| Current Ratio (MRQ) | 1.77 |
| Operating Cash Flow (TTM) | 26.41 M |
| Levered Free Cash Flow (TTM) | 33.42 M |
| Return on Assets (TTM) | -4.53% |
| Return on Equity (TTM) | -16.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Assertio Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | -0.50 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.07% |
| % Held by Institutions | 29.62% |
| 52 Weeks Range | ||
| Median | 3.50 (438.46%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Mar 2025 | 3.50 (438.46%) | Buy | 0.710 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 May 2025 | Announcement | Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 |
| 21 Mar 2025 | Announcement | iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 |
| 20 Mar 2025 | Announcement | Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 |
| 12 Mar 2025 | Announcement | Assertio Reports Fourth Quarter and Full Year 2024 Financial Results |
| 05 Mar 2025 | Announcement | Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |